recombinant Factor C (rFC) Assay is an
animal-free alternative to LAL that has been accepted by the FDA as an
The PyroGene™ rFC Assay does not use horseshoe crab blood as the
raw material, therefore, there is less dependence on the animal, which results
in less animal utilization.
Comparable Endotoxin Detection Method to
Accepted by the FDA,
European Pharmacopeia and other leading regulatory authorities, the recombinant
Factor C method is a recognized, comparable endotoxin detection method to
LAL-based assays. Based on the activation of a recombinant form of Factor
C, the first component in the horseshoe crab clotting cascade, the PyroGene™
rFC Assay offers the same reliability as an LAL method – without the use of animal resources.
White Paper: PyroGene™ Recombinant
Factor C Assay
Endotoxin Testing: It’s Time to Embrace the Alternative
- The growing demand of a natural resource
- Benefits of the synthetic version of Factor C
- How to validate PyroGene™ rFC Assay
Download White Paper
Watch How to Perform the PyroGene™ recombinant Factor C Assay
of the PyroGene™ rFC Assay
- Endotoxin specific,
recombinant technology eliminates false-positive glucan reactions
- Predictable, reliable
lot-to-lot assay performance
- Sustainable resource –
no animal utilization
- Endpoint fluorescent
assay, comparable to other quantitative LAL methods
- 510(K) submissions have
been approved by the FDA using PyroGene™ rFC Assay as a final release test
Comprehensive FDA Master File
Request Validation Protocol
The Case for Recombinant Factor C: Primed for the Big Time
Lonza’s Dr. Elena Gustchina will co-present with Jay Bolden, Eli Lilly at the PDA Europe Pharmaceutical Microbiology’s Challenge Summit, “The Case for Recombinant Factor C – Primed for the Big Time,” 14 Feb 2017, Porto Portugal. Elena will also be showcasing a poster entitled, “Pushing the Limits of the PyroGene™ recombinant Factor C Assay,” to demonstrate recent improvements to the PyroGene™ Assay platform.
Pharmacopeia Chapter 5.1.10 Now Effective!
The proposed revision of Ph. Eur. chapter 5.1.10, which included language to support the use of recombinant
Factor C as alternative test method to the LAL test, was adopted by the
European Pharmacopoeia Commission during its 152nd session in
Strasbourg on 16-17 June 2015. The
revised chapter 5.1.10 became effective on 1st July 2016 in
the 37 European signatory States and will be published in Supplement 8.8.
The rFC assay will still be considered an “Alternative Test”,
subject to the validation requirements of USP <1225> or ICH Q2B.
Regulatory authorities will accept the test results of the rFC
assay, but a validation study must be performed, per product. Validation studies are used to compare the
alternative and compendial method, and verify the equivalence between the two
methods of the assay. Post-validation, it is necessary to follow up with
the appropriate regulatory filing for the drug product or device.
Learn more about the regulatory status of the PyroGene™ Recombinant Factor C Assay.